drugset / Trial / NCT01682161

A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate

NCT01682161

Phase 4 Completed 154 enrolled Janssen Korea, Ltd., Korea
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the change of medication satisfaction measured by Medication Satisfaction Questionnaire (MSQ) from baseline to endpoint for patients who are switched into paliperidone palmitate, either immediately or in a delayed mode.

Timeline

Start
2012-01
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject paliperidone palmitate Unknown 25 mg
Subject paliperidone palmitate Unknown 75 mg
Subject paliperidone palmitate Unknown 150 mg

Indications